Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 15/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.63 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043899 | 0.97 | HCAR3 (1.00) | HCAR3KMT2AMEN1LMNAGPR55 | |
| SCHEMBL2030586 | 0.96 | HCAR3 (0.97) | HCAR3KMT2AMEN1LMNAGPR55 | |
| SCHEMBL5906517 | 0.94 | HCAR3 (1.00) | HCAR3KMT2AMEN1LMNAGPR55 | |
| SCHEMBL2687469 | 0.89 | HCAR3 (0.84) | HCAR3KMT2AMEN1LMNAGPR55 | |
| SCHEMBL5838082 | 0.87 | HCAR3 (0.76) | HCAR3KMT2AMEN1LMNAGPR55 | |
| SCHEMBL1725095 | 0.86 | HCAR3 (0.80) | HCAR3KMT2AMEN1LMNAGPR55 | |
| SCHEMBL4136830 | 0.86 | HCAR3 (0.80) | HCAR3KMT2AMEN1LMNAGPR55 | |
| SCHEMBL3497824 | 0.85 | HCAR3 (0.78) | HCAR3KMT2AMEN1LMNAGPR55 | |
| SCHEMBL24704181 | 0.84 | HCAR3 (0.81) | HCAR3KMT2AMEN1LMNAGPR55 | |
| SCHEMBL25782087 | 0.83 | HCAR3 (0.74) | HCAR3KMT2AMEN1LMNAGPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885KMT2A 2238/4885MEN1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.